Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Chronic pyelonephritis" patented technology

Chronic pyelonephritis is persistent kidney inflammation that can scar the kidneys and may lead to chronic renal failure. This disease is most common in patients who are predisposed to recurrent acute pyelonephritis, such as those with urinary obstructions or vesicoureteral reflux.

High dosage tebipenem pivoxil tablet formulation

The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w / w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w / w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w / w tebipenem pivoxil HBr, 5-25% w / w of a diluent, 0.5 to 5% w / w of a glidant, 0.5 to 5% w / w of a lubricant, and optionally 0.5 to 5% w / w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.
Owner:SPERO THERAPEUTICS INC

Method of treating focal segmental glomerulosclerosis

ActiveUS12194032B2Organic chemistryAntibody ingredientsDiseaseAnabolic steroid
A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.
Owner:CHEMOCENTRYX INC

ATP production promoter

PendingJP2026104708AOrganic active ingredientsSenses disorderChronic kidney failureGitelman syndrome
To provide an ATP production promoter useful for preventing or treating diseases associated with decreased ATP production, particularly renal impairment. [Solution] The present invention comprises an ATP production promoter containing a component having URAT1 inhibitory activity. Preferably, the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad. The present invention is expected to be useful as a preventive and therapeutic agent for diseases of decreased ATP production, and is particularly useful as a therapeutic and / or preventive agent for nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia nephropathy, autosomal dominant tubulointerstitial kidney disease, nephronoplasia, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.
Owner:THE UNIV OF TOKYO +1